Table 2.
Characteristics related to prior and retreatment anti-EGFR regimens
| Characteristic | N/total # pts (%) |
|---|---|
| Response on prior anti-EGFR therapy | |
| Response or stable disease ≥6 m | 37/89 (42) |
| No response or stable disease <6 m | 52/89 (58) |
| Clinical benefit on anti-EGFR retreatment | |
| Best response CR/PR/SD | 50/86 (58) |
| Best response PD | 36/86 (42) |
| Prior anti-EGFR-based regimens | |
| Panitumumab monotherapy | 6/89 (7) |
| Panitumumab + Chemotherapya | 9/89 (10) |
| Panitumumab and AMG-102/AMG-479 | 1/89 (1) |
| Cetuximab monotherapy | 2/89 (2) |
| Cetuximab + Chemotherapyb | 71/89 (80) |
| Anti-EGFR-based retreatment regimens | |
| Cetuximab, FOLFOX, and dasatinib | 31/89 (35) |
| Cetuximab, irinotecan, and bevacizumab | 12/89 (13) |
| Cetuximab and erlotinib | 13/89 (15) |
| Cetuximab and sirolimus | 11/89 (12) |
| Cetuximab, HAIc oxaliplatin, 5-FU, bevacizumab | 20/89 (23) |
| Cetuximab, HAI oxaliplatin, and bevacizumab | 2/89 (2) |
| Interval length between prior and retreatment anti-EGFR therapies | Months |
| Median | 4.57 |
| Mean ± Standard Deviation | 7.34 ± 8.9 |
| Range | 0.46 – 58.7 |
aChemotherapy regimen: irinotecan (7), FOLFIRI (1), 5-FU and irinotecan (1)
bChemotherapy regimen: Irinotecan (42), FOLFIRI (15), FOLFOX (5), irinotecan and arq197 (3), irinotecan and apomab (1), irinotecan and bevacizumab (3), FOLFOX and dasatinib (1), Xelox (1)
cHAI = Hepatic Arterial Infusion